Carol Krantz

Carol Krantz is Executive Director Regulatory Affairs, CMC at Pfizer. Carol is the former Head of Regulatory CMC at Seagen, which was acquired by Pfizer December 2023. During her 7 years at Seagen, Carol built a Regulatory CMC group specializing in ADCs and small molecules who helped gain approval for PADCEV, TUKYSA and TIVDAK while supporting global and franchise expansion of these products and an expanding pipeline. Prior to Seagen, Carol was a Regulatory CMC leader Amgen with portfolio oversight of development and commercial stage products including ENBREL, VECTIBIX and IMLYGIC. Before being acquired by Amgen, Carol was at Immunex and held positions in Regulatory, Process Development, Project Management and Supply Chain. She also has served as an independent Regulatory CMC consultant for BioNow Consulting and was the Regulatory CMC lead at Sierra Oncology. Carol received a B.A. in Biology from the University of Pennsylvania, her Ph.D. in Immunology/Microbiology from the University of Colorado, Health Sciences Center and did her post-doctoral studies at the Fred Hutchinson Cancer Research Center.